Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1021-1040 of 2,251 trials

Overactive Bladder in Children: BeDry Study

We are testing solifenacin, mirabegron, and their combination for treating daytime urinary incontinence in children aged 5 to 14. The study aims to see how well these treatments work and their effects on safety and quality of life.

Daytime Urinary Incontinence3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesPediatricsUrology

Acute Agitation: Comparing New Medications

We are studying how well sublingual dexmedetomidine and buccal midazolam work for calming patients in emergency settings compared to oral lorazepam. We also want to know about their safety and how satisfied patients feel with these treatments.

Acute Agitation>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPsychiatry

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

Recurrent Glioblastoma1-2 yearsSafety phase (I)No PlaceboStandard MedicinesNeurologyOncology

GSDIa: DTX401 Treatment Study

We are examining the long-term safety and pregnancy outcomes of DTX401 for individuals with GSDIa. This study will help us understand how effective this treatment is over time.

Glycogen Storage Disease Type IA>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Multiple Sclerosis: Stem Cell Treatment Study

We are investigating whether a new stem cell treatment can help regenerate nerve function in patients with progressive multiple sclerosis. The study will also assess safety and other health measures.

Multiple Sclerosis>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurology

BCR/ABL1-Like Acute Lymphoblastic Leukemia: Ponatinib and Chemotherapy

We are studying a new treatment combining ponatinib and chemotherapy for adults with BCR/ABL1-like acute lymphoblastic leukemia. The aim is to improve remission rates and monitor disease response over time.

Acute Lymphoblastic LeukemiaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Rare Cancers: Dendritic Cell Vaccine Study

We are testing a new vaccine made from patients' own tumor cells for those with resected stage IV neuroendocrine tumors and soft tissue sarcomas. The study aims to evaluate safety and how well the immune system responds to the treatment.

Soft Tissue SarcomaNeuroendocrine Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Solid Tumors: E7386 with Other Anticancer Drugs

We are studying the safety and effectiveness of E7386 combined with other anticancer treatments for patients with solid tumors. This trial aims to find the best dose and assess how well it works compared to standard therapies.

Liver Cancer (Hepatocellular Carcinoma)Colorectal CancerEndometrial CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Oral Midazolam for Patients Refusing Care

We are studying whether oral midazolam can help older patients with moderate to severe cognitive disorders accept necessary care. The trial also looks at its safety and the satisfaction of healthcare providers.

Cognitive Issues and Agitation in the Elderly>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyPsychiatry

Urinary Incontinence in Children: StayDry Study

We are exploring how stopping medication for urinary incontinence affects recurrence and overall well-being in children. The study compares abrupt versus gradual withdrawal of treatments like solifenacin and mirabegron.

Daytime Urinary Incontinence>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesUrology

Chronic Lymphocytic Leukemia: Venetoclax and Pirtobrutinib Study

We are comparing different treatment plans for newly diagnosed chronic lymphocytic leukemia patients to see if a personalized approach improves outcomes. This includes assessing how long patients can stay in remission and the overall effectiveness of the treatments.

Chronic Lymphocytic Leukaemia (CLL)Small Lymphocytic Lymphoma (SLL)>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Inflammatory Diseases: Low-Dose Interleukin-2 Therapy

We are studying the safety and effectiveness of low-dose interleukin-2 therapy for patients with conditions like Pemphigus vulgaris and Mucous Membrane Pemphigoid. This trial aims to see how well this treatment works compared to a placebo.

Primary Sclerosing Cholangitis (PSC)Mucous Membrane PemphigoidPolymyositis/Dermatomyositis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyInfectious DiseasesRheumatology

Head and Neck Cancer: Petosemtamab Treatment Study

We are studying the effects of petosemtamab in patients with advanced head and neck cancer who have not responded to previous treatments. The goal is to see if it improves survival and tumor response compared to standard therapies.

Metastatic Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Head and Neck Cancer: Petosemtamab with Pembrolizumab

We are studying a new treatment combination for patients with recurrent or metastatic head and neck cancer to see if it works better than standard treatment. This trial is for those with tumors that express PD-L1.

Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Uveal Melanoma: Tebentafusp Treatment Study

We are studying whether the drug tebentafusp can help prevent cancer recurrence in patients with high-risk uveal melanoma after surgery or radiation. This trial also looks at the safety of the treatment compared to observation.

Uveal Melanoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOphthalmology

Paroxysmal Nocturnal Hemoglobinuria: Pozelimab and Cemdisiran Therapy

We are studying the long-term safety and effectiveness of a combination therapy for adults with Paroxysmal Nocturnal Hemoglobinuria. This trial will help us understand its impact on symptoms like fatigue and hemoglobin levels.

Paroxysmal Nocturnal Hemoglobinuria>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Carvedilol vs. Flecainide for Ventricular Arrhythmias

We are comparing two medications to see which one better reduces abnormal heartbeats in people with idiopathic ventricular arrhythmias. The study also looks at how these treatments affect quality of life and any side effects.

Ventricular ExtrasystolesMonomorphic Ventricular TachycardiaIdiopathic Ventricular Arrhythmias6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiology